Fenwick & West, Goodwin Procter and Maiwald represented Royalty Pharma in the transaction, Wilmer Cutler Pickering Hale and Dorr represented PTC Therapeutics. Royalty Pharma plc (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Fenwick and Goodwin represented Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry,...
You must be a Standard 1 Year member to access this content.
Goodwin advised Royalty Pharma plc on the deal. Royalty Pharma plc (Nasdaq: RPRX) announced its definitive agreement to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from...
You must be a Standard 1 Year member to access this content.
Skadden advised Theravance Biopharma, while Goodwin Procter advised Royalty Pharma on the deal. Willkie Farr & Gallagher advised Innoviva on the sale of its stake in...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised TA Associates on the deal. TA Associates announced its strategic growth investment in Veracode, taking a majority equity position in the business. Veracode is...
You must be a Standard 1 Year member to access this content.
Cravath and Saraf and Partners represented Viatris in the transaction while Shardul Amarchand Mangaldas & Co and Goodwin Procter advised Biocon Biologics. Viatris Inc. reached a...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised TrueMotion on the deal. TrueMotion announced its acquisition by Cambridge Mobile Telematics. The transaction, which closed on June 16, unites the two leading...
You must be a Standard 1 Year member to access this content.
Wachtell, Lipton, Rosen & Katz and Willkie Farr & Gallagher advised Constellation on the deal. Goodwin Procter, Dechert and Maiwald acted as legal advisors to Royalty...
You must be a Standard 1 Year member to access this content.
